Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Kedudukan dalam Saham #14767
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Harga Saham
$16.85
Disegerakkan terakhir: 2023-07-07
Modal Pasaran
$393.50M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CH
Perdagangan VectivBio Holding AG (VECT)

Kategori

Sejarah hasil dividen untuk VectivBio Holding AG (VECT)
Hasil dividen (TTM) bagi VectivBio Holding AG (simbol saham: VECT) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk VectivBio Holding AG (VECT) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
0.00%
US
0.00%
NL
2.48%
AU
0.00%
US
0.00%
CH